miRNA biomarker | GenomeWeb

miRNA biomarker

Researchers from Northwestern University uncovered five circulating microRNAs that differentiate patients with very high- and low-risk prostate cancer.

A team of German researchers identified the four-microRNA signature and said it might inform treatment decisions.

The company sees microRNAs as the ideal blood-based biomarker for diagnosing and monitoring a number of diseases at the point of care and in the developing world.

The test could provide an early diagnosis of breast cancer by examining a handful of miRNA, microRNA, and proteomic biomarkers from urine samples. 

The International Thyroid Congress and Annual Meeting of the American Thyroid Association announced studies validating diagnostics tests for several companies.

NIH researchers have uncovered a blood-based microRNA signature that may be able to tell which patients with precursor disease may progress to myeloma.

The grant is being provided under the NIH's Extracellular RNA Communication program, which was set up to study the role of molecules such as microRNAs.

The company has begun establishing partnerships with medical centers for a large prospective study of its test for identifying aggressive tumors.

The partners will try to validate the ability of has-miR-31-3p to predict which patients may benefit from anti-EGFR therapy.

NEW YORK (GenomeWeb) – Danish miRNA biomarker firm Exiqon today reported its first quarter revenues were up 2 percent year over year.


In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.